Janus kinase inhibitors: between prescription authorization and reimbursability by F.R. Spinelli, F. Conti, R. Caporali, F. Iannone, F. Cacciapaglia, on behalf of the Steering Committee of the Italian Society of Rheumatology

Subjects: “…Janus kinase inhibitors…”
Get full text

Inhibition of retinopathy of prematurity in rat by intravitreal injection of sorafenib by Li-Li Tian, Bing Ren, Xiao-Wei Gao, Ying Luo, Yan Cai, Kun Zhou, An-Jie Du, Yong Zhao

Subjects: Get full text

Editorial: Recent advances in the research and development of kinase-inhibitory anticancer molecules by Ahmed A. Al-Karmalawy, Ahmed A. Al-Karmalawy, Hussein I. El-Subbagh, Hussein I. El-Subbagh, Liliya Logoyda, Roman B. Lesyk, Mohammed I. El-Gamal, Mohammed I. El-Gamal, Mohammed I. El-Gamal

Subjects: Get full text

Improved Synthesis of Substituted 6,7-Dihydroxy-4-quinazolineamines: Tandutinib, Erlotinib and Gefitinib by Ulrich Jordis, Dirk Röseling, Petr Knesl

Subjects: Get full text

Pharmacokinetic Boosting of Kinase Inhibitors by Niels Westra, Daan Touw, Marjolijn Lub-de Hooge, Jos Kosterink, Thijs Oude Munnink

Subjects: Get full text

JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician by Abigail Beard, Shannon C. Trotter

Subjects: Get full text

Concurrent hand-foot skin reaction and hair depigmentation with sunitinib: Report of a case and literature review of kinase inhibitors and blocking antibodies by Shuchi Bansal, Kabir Sardana, Kishore Singh, Vijay K Garg

Subjects: Get full text

Clinical Profile of Non-thyroidal Cancer Patients with Tyrosine Kinase Inhibitor-Induced Thyroid Dysfunction in the University of Santo Tomas Hospital, Philippines by Nenuel Angelo Luna, Jennilyn Quinitio, Erick Mendoza, Sjoberg Kho, Priscilla Caguioa

Subjects: “…tyrosine kinase inhibitors…”
Get full text

NTRK fusions in osteosarcoma are rare and non‐functional events by Baptiste Ameline, Karim H Saba, Michal Kovac, Linda Magnusson, Olaf Witt, Stefan Bielack, Michaela Nathrath, Karolin H Nord, Daniel Baumhoer

Subjects: Get full text

Kinase Inhibitors in the Treatment of Thyroid Cancer: Institutional Experience by Matea Pešorda, Sanja Kusačić Kuna, Dražen Huić, Davorin Herceg, Marija Despot, Tatjana Samardžić, Milena Gnjidić, Borislav Belev

Subjects: Get full text

Current perspectives in tackling glaucoma blindness by Shibal Bhartiya, Parul Ichhpujani, Meenakshi Wadhwani

Subjects: Get full text

Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis by Carnero Contentti E, Correale J

Subjects: Get full text

Design, synthesis and biological activity of N4-phenylsubstituted-7H-pyrrolo[2,3-d]pyrimidin-4-amines as dual inhibitors of aurora kinase A and epidermal growth factor receptor kin... by Sonali Kurup, Bradley McAllister, Pavlina Liskova, Trusha Mistry, Anthony Fanizza, Dan Stanford, Jolanta Slawska, Ulrich Keller, Alexander Hoellein

Subjects: Get full text

Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer? by Tommaso Porcelli, Cristina Luongo, Anna Cerbone, Carmine Di Luccio, Mariantonia Nacchio, Maria Angela De Stefano, Martin Schlumberger, Domenico Salvatore

Subjects: Get full text

Clinicopathological Characteristics and Real-life Data of Patients Receiving Tyrosine Kinase Inhibitor in Metastatic EGFR Mutant Non-small Cell Lung Carcinoma by Barış EKİNCİ, Nebi Serkan DEMİRCİ

Subjects: Get full text

Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma by Sojung Han, Do Young Kim

Subjects: Get full text

Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? by C Beyer, O Distler, JH Distler

Subjects: Get full text

BARICITINIB: NEW PHARMACOTHERAPY OPTIONS FOR RHEUMATOID ARTHRITIS AND OTHER IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES by E. L. Nasonov, A. M. Lila

Subjects: Get full text

Inhibitors of Discoidin Domain Receptor (DDR) Kinases for Cancer and Inflammation by William A. Denny, Jack U. Flanagan

Subjects: Get full text

Effect of vorinostat on INK4 family and HDACs 1, 2, and 3 in pancreatic cancer and hepatocellular carcinoma by Masumeh Sanaei, Fraidoon Kavoosi

Subjects: “…cyclin-dependent kinase inhibitors; neoplasms; vorinostat…”
Get full text